Dosage for Tibsovo: Form, potency, administration, and additional details
In the field of cancer treatment, a drug called Tibsovo (ivosidenib) has been making strides, particularly in the treatment of acute myeloid leukemia (AML) and bile duct cancer (cholangiocarcinoma). Here's what you need to know about the recommended dosage for these conditions.
For adults with AML, the standard dosage of Tibsovo is 500 mg orally once daily. This dosage is recommended for both newly diagnosed AML patients who are 75 years or older or have comorbidities precluding intensive chemotherapy, as well as for those with relapsed or refractory AML, provided they have an IDH1 mutation confirmed by an FDA-approved test. In some cases, Tibsovo may be used in combination with azacitidine.
For bile duct cancer, the typical dosage is also 500 mg orally once daily. This dosage is intended for adult patients who have been previously treated. It's important to note that treatment continues until disease progression or unacceptable toxicity.
When taking Tibsovo, it should be swallowed whole and not broken, crushed, or chewed. It can be taken with or without food, but not with a high fat meal. If you miss a dose and it's been more than 12 hours before your next dose is due, take your missed dose as soon as possible. However, if there are less than 12 hours until your next dose, do not take the missed dose. Take your next dose at your regularly scheduled time.
It's crucial to remember that certain medications can interact with Tibsovo, and if you take any CYP3A4 blockers, your doctor may recommend a lower dose of Tibsovo. If you have trouble reading your prescription label, ask your doctor or pharmacist about accessible drug labels and containers.
In case of overdose, call your doctor right away. If you have trouble opening medication bottles, ask your pharmacist about putting Tibsovo in an easy-open container.
In summary:
| Condition | Tibsovo Dosage | Notes | |----------------------------------|------------------------------------|-------------------------------------| | AML (newly diagnosed, older/comorbid) | 500 mg oral once daily | Monotherapy or with azacitidine[1][3] | | AML (relapsed/refractory) | 500 mg oral once daily | For IDH1 mutation[1] | | Bile duct cancer (cholangiocarcinoma) | 500 mg oral once daily (typical) | For previously treated patients[1] |
These dosing guidelines reflect FDA approvals and recent clinical trial data as of mid-2025[1][3]. Always consult with your healthcare provider for personalised advice and the latest information.
[1] FDA-approved prescribing information for Tibsovo. [3] Clinical trial data on the use of Tibsovo for AML and bile duct cancer.
- The standard dosage for Tibsovo in treatment of acute myeloid leukemia (AML) for both newly diagnosed individuals aged 75 or older or with comorbidities, as well as for those with relapsed or refractory AML with an IDH1 mutation, is 500 mg orally once daily, which may be used in combination with azacitidine in some cases.
- For bile duct cancer (cholangiocarcinoma), the typical dosage of Tibsovo, intended for adult patients who have been previously treated, is also 500 mg orally once daily, and treatment continues until disease progression or unacceptable toxicity.
